STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-related share disposition. On May 20, 2026, 97,626 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These grants were originally awarded on May 20, 2024, March 21, 2025 and March 20, 2026. After this withholding, Egholm directly holds 6,597,956 shares of common stock, indicating this was a compensation- and tax-driven event rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Egholm Michael

Role President & CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	97,626	$1.00	$98K

Holdings After Transaction: Common Stock — 6,597,956 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares withheld for taxes: 97,626 shares Per-share value for withholding: $1.00 per share Shares held after transaction: 6,597,956 shares

3 metrics

Shares withheld for taxes 97,626 shares Withheld on May 20, 2026 to satisfy tax withholding obligations

Per-share value for withholding $1.00 per share Reported transaction price for withheld common stock

Shares held after transaction 6,597,956 shares Common stock directly held by Michael Egholm following tax withholding

Key Terms

restricted stock units, tax withholding obligations, Form 4

3 terms

restricted stock units financial

"the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting"

Form 4 regulatory

"which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Egholm Michael

(Last)

(First)

(Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		F		97,626⁽¹⁾	D	$1	6,597,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, March 21, 2025 and March 20, 2026, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024, March 24, 2025 and April 8, 2026, respectively.

	/s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did STANDARD BIOTOOLS (LAB) report for Michael Egholm?

STANDARD BIOTOOLS President & CEO Michael Egholm reported a tax-related disposition of shares. On May 20, 2026, 97,626 common shares were withheld to cover tax obligations from vesting restricted stock units granted in 2024, 2025 and 2026.

Was the STANDARD BIOTOOLS (LAB) Form 4 transaction an open-market sale?

No, the Form 4 transaction was not an open-market sale. Shares were withheld by the company to satisfy tax withholding obligations triggered by vesting restricted stock units, a routine compensation-related event rather than a discretionary sale in the open market.

How many STANDARD BIOTOOLS (LAB) shares were withheld for taxes and at what price?

A total of 97,626 STANDARD BIOTOOLS common shares were withheld for taxes at a reported value of $1.00 per share. This withholding covered tax liabilities from the vesting of several restricted stock unit grants to the CEO.

How many STANDARD BIOTOOLS (LAB) shares does Michael Egholm hold after the Form 4 transaction?

After the tax-withholding disposition, Michael Egholm directly holds 6,597,956 shares of STANDARD BIOTOOLS common stock. This post-transaction figure reported in the Form 4 shows he retains a substantial equity position following the routine tax-related share withholding.

What caused the tax withholding reported in the STANDARD BIOTOOLS (LAB) Form 4?

The tax withholding arose when restricted stock units granted to Michael Egholm vested. These RSU grants were originally awarded on May 20, 2024, March 21, 2025 and March 20, 2026, and vesting triggered tax obligations settled by withholding company shares.